- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00953199
Topical Pancreatic Duct Lidocaine for Prevention of Post-ERCP Pancreatitis
A Single Center, Randomized, Double-Blind Controlled Study of Topical Endoluminal Pancreatic Duct Lidocaine for Prevention of Post-ERCP Pancreatitis
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Post endoscopic retrograde cholangiopancreatography (ERCP) pancreatitis is a common cause of morbidity for which there is no known pharmacologic prophylaxis. Post-ERCP pancreatitis is thought to be caused by several factors, including intraductal pressure, multiple duct injections with contrast, and neural arc reflexes. Lidocaine is a safe, inexpensive class IV antiarrhythmic that has topical anesthetic effects, inhibits trypsin activity, and may potentially prevent post-ERCP pancreatitis by injection directly into the pancreatic duct at the time of ERCP. Lidocaine has been shown to inhibit phospholipase A2, a key pancreatic enzyme, interrupt local arc reflexes to stop neuronal transmission, and to dampen GI tract mucosal reflexes to prevent high ductal pressure.
The key objective of this study is to determine if injection of lidocaine is beneficial in preventing post-ERCP pancreatitis. Subjects will be randomized to study group or control group in an equal ratio. The physicians performing the ERCP will be unaware of the treatment group to which patients have been assigned. Study arm will receive contrast agent Diatrizoate 60% (5 ml) diluted with lidocaine 2% (5 ml) during ERCP. Control arm will receive contrast agent Diatrizoate 60% (5 ml) diluted with normal saline 0.9% (5 ml) during ERCP. Diatrizoate diluted with normal saline is the standard of care. Patients will be contacted 1 day and 1 week post-ERCP to assess for symptoms of pancreatitis.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Pennsylvania
-
Hershey, Pennsylvania, United States, 17033
- Penn State College of Medicine, Penn State Milton S. Hershey Medical Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patients included are >18 years old, referred to Endoscopy Clinic for an ERCP for any well established indication such as: biliary strictures, benign and malignant hepato-pancreato-biliary tumors, chronic pancreatitis, and suspected sphincter of Oddi dysfunction
Exclusion Criteria:
- Known sensitivity to lidocaine or contrast agent
- History of seizure disorder
- History of cardiac arrhythmia (tachyarrhythmia, bradyarrhythmia, cardiac conduction defects, prolonged QT syndrome)
- History of congestive heart failure
- Active acute pancreatitis before procedure
- Planned biliary stent removal without pancreatogram
- Pregnancy
- Incarcerated individuals
- Less than 18 years of age
- Previous sphincterotomy
- Inability to give informed consent
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Lidocaine
Study subjects receive a 1:1 combination of 5 ml Diatrizoate 60% and 5 ml Lidocaine Hydrochloride 2%
|
1:1 combination of contrast dye Diatrizoate 60% (5 ml) diluted with lidocaine 2% (5 ml) used at ERCP.
Lidocaine will only be used once, and thus a maximum dose of 100 mg will be employed.
If the patient requires more contrast agent, this will be used without the addition of lidocaine.
|
Active Comparator: Normal Saline
The control arm receives a 1:1 combination of 5 ml Diatrizoate and 5ml saline.
|
1:1 combination of contrast dye Diatrizoate 60% (5 ml) diluted with normal saline 0.9% (5 ml) used at ERCP (standard of care).
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Post ERCP Pancreatitis is the Primary Outcome.
Time Frame: 24-48 hours post-procedure
|
The primary outcome of interest will be development of acute pancreatitis defined as new or worsening abdominal pain post-ERCP associated with an increase in serum amylase at least 3 times the upper limit of normal.
|
24-48 hours post-procedure
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Serum Amylase Levels
Time Frame: measurement is taken 2 hrs after ERCP
|
serum amylase levels are measure by a blood draw
|
measurement is taken 2 hrs after ERCP
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Abraham Mathew, M.D., M.S., Milton S. Hershey Medical Center
Publications and helpful links
General Publications
- Cosen-Binker LI, Binker MG, Negri G, Tiscornia O. Acute pancreatitis possible initial triggering mechanism and prophylaxis. Pancreatology. 2003;3(6):445-56. doi: 10.1159/000074972. Epub 2003 Nov 19.
- Kiyonari Y, Nishina K, Mikawa K, Maekawa N, Obara H. Lidocaine attenuates acute lung injury induced by a combination of phospholipase A2 and trypsin. Crit Care Med. 2000 Feb;28(2):484-9. doi: 10.1097/00003246-200002000-00033.
- Makela A, Kuusi T, Schroder T. Inhibition of serum phospholipase-A2 in acute pancreatitis by pharmacological agents in vitro. Scand J Clin Lab Invest. 1997 Aug;57(5):401-7. doi: 10.3109/00365519709084587.
- Portiansky EL, Gonzalez PH. Protective effect of lidocaine in the experimental foot-and-mouth disease pancreatitis. Experientia. 1995 Nov 15;51(11):1060-2. doi: 10.1007/BF01946916.
- Schroder T, Kinnunen PK, Lempinen M. Xylocaine treatment in experimental pancreatitis in pigs. Scand J Gastroenterol. 1978;13(7):863-5. doi: 10.3109/00365527809182204.
- Schwartz JJ, Lew RJ, Ahmad NA, Shah JN, Ginsberg GG, Kochman ML, Brensinger CM, Long WB. The effect of lidocaine sprayed on the major duodenal papilla on the frequency of post-ERCP pancreatitis. Gastrointest Endosc. 2004 Feb;59(2):179-84. doi: 10.1016/s0016-5107(03)02540-9.
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Digestive System Diseases
- Pancreatic Diseases
- Pancreatitis
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Anti-Arrhythmia Agents
- Central Nervous System Depressants
- Peripheral Nervous System Agents
- Sensory System Agents
- Anesthetics
- Membrane Transport Modulators
- Anesthetics, Local
- Voltage-Gated Sodium Channel Blockers
- Sodium Channel Blockers
- Lidocaine
Other Study ID Numbers
- Lidocaine
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Pancreatitis
-
Changhai HospitalUnknownChronic Pancreatitis | Idiopathic Chronic PancreatitisChina
-
Centre Hospitalier Universitaire de NiceRecruiting
-
Copenhagen University Hospital, HvidovreRecruitingFibrosis | Inflammation | Pancreatitis | Chronic Pancreatitis | Acute Pancreatitis | Recurrent PancreatitisDenmark
-
Tianjin Nankai HospitalCompletedAcute PancreatitisChina
-
Massachusetts General HospitalTerminatedChronic Pancreatitis | Acute Recurrent PancreatitisUnited States
-
Changhai HospitalEnrolling by invitationChronic Pancreatitis | Acute Pancreatitis | Healthy PeopleChina
-
Postgraduate Institute of Medical Education and...Completed
-
Dartmouth-Hitchcock Medical CenterCompleted
-
The Cleveland ClinicChiRhoClin, Inc.; The National Pancreas FoundationCompletedChronic PancreatitisUnited States
Clinical Trials on Lidocaine Hydrochloride
-
Rajmonda Nallbani-KomoniUnknownAnalgesic Drug DependenceKosovo
-
Lahey ClinicWithdrawn
-
Gil YosipovitchTerminated
-
Hospital de BaseCompleted
-
Tianjin Medical University General HospitalCompleted
-
Zeng ChanghaoRecruiting
-
Carilion ClinicWithdrawn
-
The Catholic University of KoreaWithdrawnthe Effect of Dexmedetomidine and Licodaine on Acute Postoperative Pain in Gynecological LaparoscopyGynecologic DiseaseKorea, Republic of
-
University Health Network, TorontoCompletedUterine LeiomyomasCanada
-
Jinling Hospital, ChinaCompleted